MM-102 TFA

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555880

CAS#: 1883545-52-5 (TFA)

Description: MM-102 is a Potent WDR5/MLL interaction inhibitor. The MM-102 compound prevents the interaction between mixed lineage leukemia 1 (MLL1) and WD Trp-Asp repeat domain 5 (WDR5) and results in the inhibition of MLL1 H3K4 histone methyltransferase (HMT) activity. Down-Regulation of H3K4me3 by MM-102 Facilitates Epigenetic Reprogramming of Porcine Somatic Cell Nuclear Transfer Embryos

Price and Availability

Size Price Shipping out time Quantity
25mg USD 450 2 Weeks
50mg USD 750 2 Weeks
100mg USD 1250 2 Weeks
200mg USD 1950 2 Weeks
500mg USD 3650 2 Weeks
1g USD 4650 2 Weeks
2g USD 7650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-12-02. Prices are subject to change without notice.

MM-102 TFA is in stock.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 555880
Name: MM-102 TFA
CAS#: 1883545-52-5 (TFA)
Chemical Formula: C37H50F5N7O6
Exact Mass:
Molecular Weight: 783.842
Elemental Analysis: C, 56.70; H, 6.43; F, 12.12; N, 12.51; O, 12.25

Related CAS #: 1417329-24-8 (free base)   1883545-52-5 (TFA)    

Synonym: MM-102 TFA; MM-102 trifluoroacetic acid; MM-102; MM 102; MM102;

IUPAC/Chemical Name: 1-[[(2S)-5-[(Aminoiminomethyl)amino]-2-[[2-ethyl-2-[(2-methyl-1-oxopropyl)amino]-1-oxobutyl]amino]-1-oxopentyl]amino]-N-[bis(4-fluorophenyl)methyl]-cyclopentanecarboxamide trifluoroacetate


InChi Code: InChI=1S/C35H49F2N7O4.C2HF3O2/c1-5-34(6-2,43-29(45)22(3)4)31(47)41-27(10-9-21-40-33(38)39)30(46)44-35(19-7-8-20-35)32(48)42-28(23-11-15-25(36)16-12-23)24-13-17-26(37)18-14-24;3-2(4,5)1(6)7/h11-18,22,27-28H,5-10,19-21H2,1-4H3,(H,41,47)(H,42,48)(H,43,45)(H,44,46)(H4,38,39,40);(H,6,7)/t27-;/m0./s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message

Sent On: Wed Nov 04 11:48:53 2020

Search: MM102

20 selected items

PubMed Results
Items 1-20 of 20 (Display the 20 citations in PubMed)

1: Han X, Xiang J, Li C, Wang J, Wang C, Zhang Y, Li Z, Lu Z, Yue Y, Li X. MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro- fertilized embryos. Theriogenology. 2020 Apr 1;146:58-70. doi: 10.1016/j.theriogenology.2020.01.051. Epub 2020 Jan 29. PMID: 32059151.

2: Shimoda H, Doi S, Nakashima A, Sasaki K, Doi T, Masaki T. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16INK4a. Kidney Int. 2019 Nov;96(5):1162-1175. doi: 10.1016/j.kint.2019.06.021. Epub 2019 Aug 1. PMID: 31570196.

3: Zhang Z, Zhai Y, Ma X, Zhang S, An X, Yu H, Li Z. Down-Regulation of H3K4me3 by MM-102 Facilitates Epigenetic Reprogramming of Porcine Somatic Cell Nuclear Transfer Embryos. Cell Physiol Biochem. 2018;45(4):1529-1540. doi: 10.1159/000487579. Epub 2018 Feb 16. PMID: 29466785.

4: Weirich S, Kudithipudi S, Jeltsch A. Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex. Mol Oncol. 2017 Apr;11(4):373-387. doi: 10.1002/1878-0261.12041. Epub 2017 Mar 10. PMID: 28182322; PMCID: PMC5527479.

5: Cai M, Bompada P, Atac D, Laakso M, Groop L, De Marinis Y. Epigenetic regulation of glucose-stimulated osteopontin (OPN) expression in diabetic kidney. Biochem Biophys Res Commun. 2016 Jan 1;469(1):108-113. doi: 10.1016/j.bbrc.2015.11.079. Epub 2015 Nov 22. PMID: 26592666.

6: Kim DS, Rashsuren O, Kim EK. Conversion coefficients for the estimation of effective dose in cone-beam CT. Imaging Sci Dent. 2014 Mar;44(1):21-9. doi: 10.5624/isd.2014.44.1.21. Epub 2014 Mar 19. Erratum in: Imaging Sci Dent. 2014 Sep;44(3):255-6. PMID: 24701455; PMCID: PMC3972402.

7: Karatas H, Townsend EC, Cao F, Chen Y, Bernard D, Liu L, Lei M, Dou Y, Wang S. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein- protein interaction. J Am Chem Soc. 2013 Jan 16;135(2):669-82. doi: 10.1021/ja306028q. Epub 2012 Dec 27. PMID: 23210835; PMCID: PMC5180416.

8: Ashizawa T, Shimizu M, Gomi K, Okabe M. Antitumor activity of KW-2170, a novel pyrazoloacridone derivative. Anticancer Drugs. 1998 Mar;9(3):263-71. doi: 10.1097/00001813-199803000-00009. PMID: 9625437.

9: Maru M, Haraguchi M, Higashi H, Kato S, Kurimura T, Naiki M, Wakamiya N. Anti-tumor activity of ceramides and glycosphingolipids in a murine tumor system. Int J Cancer. 1993 Feb 20;53(4):645-50. doi: 10.1002/ijc.2910530420. PMID: 8436438.

10: Matsunaga K, Morita I, Iijima H, Endo H, Oguchi Y, Yoshimura M, Fujii T, Yoshikumi C, Nomoto K. Competitive action of a biological response modifier, PSK, on a humoral immunosuppressive factor produced in tumor-bearing hosts. J Clin Lab Immunol. 1990 Mar;31(3):127-36. PMID: 1966997.

11: Shiio T, Ohishi K, Tsuchiya Y, Niitsu I, Hayashibara H, Yoshihama T, Moriyuki H. [Combined use of lentinan with X-ray therapy in an experimental mouse tumor system (Part 2). Combined effect on the MM102 syngeneic tumor]. Gan To Kagaku Ryoho. 1988 Mar;15(3):475-9. Japanese. PMID: 3348633.

12: Yoshimoto R, Kondoh N, Isawa M, Hamuro J. Plant lectin, ATF1011, on the tumor cell surface augments tumor-specific immunity through activation of T cells specific for the lectin. Cancer Immunol Immunother. 1987;25(1):25-30. doi: 10.1007/BF00199297. PMID: 3496156.

13: Matsunaga K, Morita I, Oguchi Y, Fujii T, Yoshikumi C, Nomoto K. [Competitive effect of PSK against the immunosuppressive effect induced in the sera of mice bearing syngeneic tumors]. Gan To Kagaku Ryoho. 1986 Dec;13(12):3461-7. Japanese. PMID: 3789757.

14: Kawase I, Komuta K, Ogura T, Fujiwara H, Hamaoka T, Kishimoto S. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies. Cancer Res. 1985 Apr;45(4):1663-8. PMID: 3978634.

15: Toge T, Hamamoto S, Nakane H, Seto Y, Itagaki E, Hattori T. The enhancement of tumor cell susceptibility to macrophage binding and cytolysis by p-aminobenzoic acid-N-xyloside sodium salt (K-247). Int J Immunopharmacol. 1984;6(1):55-9. doi: 10.1016/0192-0561(84)90035-3. PMID: 6609891.

16: Kinouchi T, Fujiwara H, Hamaoka T. Expression of differentiation antigens cross-reactive with Ly-6.2 alloantigens on MM102 mouse mammary tumor cells. Gan. 1982 Oct;73(5):758-65. PMID: 6984683.

17: Fujiwara H, Aoki H, Tsuchida T, Hamaoka T. Immunologic characterization of tumor-associated transplantation antigens on MM102 mammary tumor eliciting preferentially helper T cell activity. J Immunol. 1978 Oct;121(4):1591-5. PMID: 308971.

18: Shimizu F, Arakawa M. Antitumor activity of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride in a variety of experimental tumors. Gan. 1978 Aug;69(4):545-8. PMID: 710804.

19: Fujiwara H, Hamaoka T, Teshima K, Aoki H, Kitagawa M. Preferential generation of killer or helper T-lymphocyte activity directed to the tumour- associated transplantation antigens. Immunology. 1976 Aug;31(2):239-48. PMID: 1085283; PMCID: PMC1445109.

20: Cyong J, Okada H. Histochemical studies on fatty acid in lymphocyte-mediated immune reaction. Immunology. 1976 May;30(5):763-7. PMID: 776819; PMCID: PMC1445032.